Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients

Journal of Surgical Oncology

Volumn 100, Issue 5, 2009, Pages 364-371

  Tamandl, Dietmar ^a   Gruenberger, Birgit ^b   Herberger, Beata ^a   Kaczirek, Klaus ^a   Gruenberger, Thomas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Liver metastases; Morbidity and mortality; Neoadjuvant chemotherapy; Recurrence; Surgery; Treatment response evaluation

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; AGING; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL EVALUATION; COLORECTAL CANCER; COMPARATIVE STUDY; FEASIBILITY STUDY; FEMALE; GROUPS BY AGE; HUMAN; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SAFETY; TREATMENT RESPONSE;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COHORT STUDIES; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MALE; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL;

EID: 70349230897     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21259     Document Type: Article

References (41)

1. Fong Y, Fortner J, Sun RL, et al.: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 1999;230:309-318; discussion 318-321. (Pubitemid 30191861)
2. Nordlinger B, Guiguet M, Vaillant JC, et al.: Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996;77:1254-1262.
3. Nagano Y, Matsuo K, Kunisaki C, et al.: Practical usefulness of ultrasonic surgical aspirator with argon beam coagulation for hepatic parenchymal transection. World J Surg 2005;29:899-902. (Pubitemid 41800725)
4. Campagnacci R, De Sanctis A, Baldarelli M, et al.: Hepatic resections by means of electrothermal bipolar vessel device (EBVS) LigaSure V: Early experience. Surg Endosc 2007;21: 2280-2284. (Pubitemid 350125959)
5. Aloia TA, Zorzi D, Abdalla EK, et al.: Two-surgeon technique for hepatic parenchymal transection of the noncirrhotic liver using saline-linked cautery and ultrasonic dissection. Ann Surg 2005;242:172-177. (Pubitemid 41033432)
6. Poon RT, Fan ST, Lo CM, et al.: Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: Analysis of 1222 consecutive patients from a prospective database. Ann Surg 2004;240:698-708; discussion 708-1610
7. Khatri VP, Petrelli NJ, Belghiti J: Extending the frontiers of surgical therapy for hepatic colorectal metastases: Is there a limit? J Clin Oncol 2005;23:8490-8499. (Pubitemid 46260246)
8. Tamandl D, Gruenberger B, Herberger B, et al.: Selective resection of colorectal liver metastases. Eur J Surg Oncol 2007;33:174-182. (Pubitemid 46336547)
9. Nagano Y, Nojiri K, Matsuo K, et al.: The impact of advanced age on hepatic resection of colorectal liver metastases. JAm Coll Surg 2005;201:511-516. (Pubitemid 41393071)
10. Laurent C, Sa Cunha A, Couderc P, et al.: Influence of postoperative morbidity on long-term survival following liver resection for colorectal metastases. Br J Surg 2003;90:1131-1136. (Pubitemid 37152173)
11. Mann CD, Neal CP, Pattenden CJ, et al.: Major resection of hepatic colorectal liver metastases in elderly patients - An aggressive approach is justified. Eur J Surg Oncol 2008;34: 428-432.
12. Hewes JC, Dighe S, Morris RW, et al.: Preoperative chemotherapy and the outcome of liver resection for colorectal metastases. World J Surg 2007;31:353-364; discussion 365-1356 (Pubitemid 46183523)
13. Adam R, Pascal G, Castaing D, et al.: Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004;240:1052-1061; discussion 1061-11054
14. Adam R, Delvart V, Pascal G, et al.: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 2004;240:644-657; discussion 657-1648 (Pubitemid 39281287)
15. Nordlinger B, Sorbye H, Glimelius B, et al.: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 2008;371:1007-1016.
16. Menon KV, Al-Mukhtar A, Aldouri A, et al.: Outcomes after major hepatectomy in elderly patients. J Am Coll Surg 2006; 203:677-683. (Pubitemid 44648785)
17. Zacharias T, Jaeck D, Oussoultzoglou E, et al.: First and repeat resection of colorectal liver metastases in elderly patients. Ann Surg 2004;240:858-865. (Pubitemid 39425780)
18. Zorzi D, Laurent A, Pawlik TM, et al.: Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007;94:274-286. (Pubitemid 46423843)
19. Ferrero A, Vigano L, Polastri R, et al.: Postoperative liver dysfunction and future remnant liver: Where is the limit? Results of a prospective study. World J Surg 2007;31:1643-1651. (Pubitemid 47063436)
20. Karoui M, Penna C, Amin-Hashem M, et al.: Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006;243:1-7. (Pubitemid 43054046)
21. Yedibela S, Elad L, Wein A, et al.: Neoadjuvant chemotherapy does not increase postoperative complication rate after resection of colorectal liver metastases. Eur J Surg Oncol 2005;31:141-146. (Pubitemid 40214748)
22. Rubbia-Brandt L, Giostra E, Brezault C, et al.: Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol 2007;18:299-304. (Pubitemid 46323097)
23. Benoist S, Brouquet A, Penna C, et al.: Complete response of colorectal liver metastases after chemotherapy: Does it mean cure? J Clin Oncol 2006;24:3939-3945.
24. Folprecht G, Grothey A, Alberts S, et al.: Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol 2005;16:1311-1319. (Pubitemid 41158476)
25. Gruenberger B, Scheithauer W, Punzengruber R, et al.: Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer 2008;8:120. (Pubitemid 351715876)
26. Falcone A, Ricci S, Brunetti I, et al.: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670-1676. (Pubitemid 46797946)
27. Diaz-Rubio E, Tabernero J, Gomez-Espana A, et al.: Phase III study of capecitabine plus oxaliplatin compared with continuousinfusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007;25:4224-4230. (Pubitemid 47548562)
28. Grothey A, Sargent D, Goldberg RM, et al.: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214. (Pubitemid 41079833)
29. Cheeseman SL, Joel SP, Chester JD, et al.: A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 2002;87:393-399.
30. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
31. Saltz LB, Lenz HJ, Kindler HL, et al.: Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study. J Clin Oncol 2007;25:4557-4561.
32. Znajda TL, Hayashi S, Horton PJ, et al.: Postchemotherapy characteristics of hepatic colorectal metastases: Remnants of uncertain malignant potential. J Gastrointest Surg 2006;10:483-489.
33. Strasberg SM: Nomenclature of hepatic anatomy and resections: A review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg 2005;12:351-355.
34. Bodingbauer M, Tamandl D, Schmid K, et al.: Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases. Br J Surg 2007;94:1133-1138. (Pubitemid 350082861)
35. Trillet-Lenoir V, Freyer G, Kaemmerlen P, et al.: Assessment of tumour response to chemotherapy for metastatic colorectal cancer: Accuracy of the RECIST criteria. Br J Radiol 2002; 75:903-908. (Pubitemid 35446457)
36. Scheele J, Stang R, Altendorf-Hofmann A, et al.: Resection of colorectal liver metastases. World J Surg 1995;19:59-71.
37. Wynne HA, Cope LH, Mutch E, et al.: The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989;9:297-301. (Pubitemid 19063317)
38. Muller-Hocker J, Aust D, Rohrbach H, et al.: Defects of the respiratory chain in the normal human liver and in cirrhosis during aging. Hepatology 1997;26:709-719. (Pubitemid 27392363)
39. Belghiti J, Hiramatsu K, Benoist S, et al.: Seven hundred fortyseven hepatectomies in the 1990s: An update to evaluate the actual risk of liver resection. J Am Coll Surg 2000;191:38-46. (Pubitemid 30439557)
40. Jarnagin WR, Gonen M, Fong Y, et al.: Improvement in perioperative outcome after hepatic resection: Analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002;236:397-406; discussion 406-1397
41. Gruenberger B, Tamandl D, Schueller J, et al.: Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastastic colorectal cancer. J Clin Oncol 2008;26:1830-1835.